Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience
Trending
- Participating Faculty: Antibody-Drug Conjugates in Advanced/Metastatic Non–Small Cell Lung Cancer
- αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells
- Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes
- EPCORE FL-1 Shows Efficacy and Safety of Epcoritamab Combination Therapy
- What Faster Pharmacokinetics Mean for Detecting Small Brain Metastases
- Fibronectin 1 mediated histone lactylation promotes malignant progression of GIST regulated by m6A modification
- Novel Agents Reshape Sequencing Across Different Lymphoma Populations
- A common stomach infection may be linked to bowel cancer – here’s what we know
Saturday, September 12
Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience
By NewsCancer
